MX2024001560A - Métodos para tratar la migraña con inhibidores de cinasa activada por mitógenos (mnk). - Google Patents
Métodos para tratar la migraña con inhibidores de cinasa activada por mitógenos (mnk).Info
- Publication number
- MX2024001560A MX2024001560A MX2024001560A MX2024001560A MX2024001560A MX 2024001560 A MX2024001560 A MX 2024001560A MX 2024001560 A MX2024001560 A MX 2024001560A MX 2024001560 A MX2024001560 A MX 2024001560A MX 2024001560 A MX2024001560 A MX 2024001560A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- methods
- treating migraine
- mnk inhibitors
- mnk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163229882P | 2021-08-05 | 2021-08-05 | |
| PCT/US2022/039529 WO2023014943A1 (en) | 2021-08-05 | 2022-08-05 | Methods of treating migraine with mnk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001560A true MX2024001560A (es) | 2024-06-26 |
Family
ID=85154787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001560A MX2024001560A (es) | 2021-08-05 | 2022-08-05 | Métodos para tratar la migraña con inhibidores de cinasa activada por mitógenos (mnk). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250205244A1 (https=) |
| EP (1) | EP4380566A4 (https=) |
| JP (1) | JP2024528982A (https=) |
| KR (1) | KR20240055743A (https=) |
| CN (1) | CN118076354A (https=) |
| AU (1) | AU2022324472A1 (https=) |
| CA (1) | CA3228265A1 (https=) |
| IL (1) | IL310590A (https=) |
| MX (1) | MX2024001560A (https=) |
| WO (1) | WO2023014943A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4646266A1 (en) * | 2023-01-04 | 2025-11-12 | 4E Therapeutics, Inc. | Solid state forms of mnk inhibitors |
| CN116735759B (zh) * | 2023-08-14 | 2023-11-07 | 南京威凯尔生物医药科技有限公司 | 一种高效液相色谱法检测乌布吉泮中间体及其对映体杂质的方法 |
| WO2026006417A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Formulations of mnk inhibitors |
| WO2026006453A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Solid dispersion formulations of mnk inhibitors |
| WO2026006442A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Deuterated mnk inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080039450A1 (en) * | 2006-06-22 | 2008-02-14 | Jensen Annika J | Compounds |
| US10280168B2 (en) * | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| TW201831479A (zh) * | 2017-01-20 | 2018-09-01 | 德商拜耳製藥公司 | 經取代二氫咪唑并吡啶二酮 |
| US20190388425A1 (en) * | 2017-01-20 | 2019-12-26 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridinpyrimidines |
| EP3972593B1 (en) * | 2019-05-23 | 2025-07-02 | Board of Regents, The University of Texas System | Inhibitor of mnk for the treatment of neuropathic pain |
-
2022
- 2022-08-05 EP EP22853939.1A patent/EP4380566A4/en active Pending
- 2022-08-05 CA CA3228265A patent/CA3228265A1/en active Pending
- 2022-08-05 IL IL310590A patent/IL310590A/en unknown
- 2022-08-05 WO PCT/US2022/039529 patent/WO2023014943A1/en not_active Ceased
- 2022-08-05 KR KR1020247007155A patent/KR20240055743A/ko active Pending
- 2022-08-05 AU AU2022324472A patent/AU2022324472A1/en active Pending
- 2022-08-05 MX MX2024001560A patent/MX2024001560A/es unknown
- 2022-08-05 CN CN202280062076.XA patent/CN118076354A/zh active Pending
- 2022-08-05 US US18/294,823 patent/US20250205244A1/en active Pending
- 2022-08-05 JP JP2024506658A patent/JP2024528982A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240055743A (ko) | 2024-04-29 |
| AU2022324472A1 (en) | 2024-02-15 |
| JP2024528982A (ja) | 2024-08-01 |
| EP4380566A4 (en) | 2025-08-27 |
| WO2023014943A1 (en) | 2023-02-09 |
| EP4380566A1 (en) | 2024-06-12 |
| US20250205244A1 (en) | 2025-06-26 |
| CA3228265A1 (en) | 2023-02-09 |
| IL310590A (en) | 2024-04-01 |
| CN118076354A (zh) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001560A (es) | Métodos para tratar la migraña con inhibidores de cinasa activada por mitógenos (mnk). | |
| MX2025011447A (es) | Inhibidores de kras | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| ZA202209563B (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2026003002A (es) | Inhibidores de kras | |
| MX2025005792A (es) | Combinaciones farmaceuticas y usos de las mismas | |
| WO2024026433A3 (en) | Novel dpp1 inhibitors and uses thereof | |
| MX2023006883A (es) | Metodos para tratar el cancer de prostata. | |
| MX2023004373A (es) | Metodos y composiciones para la degradacion dirigida de proteinas. | |
| MX2022014192A (es) | Metodos para tratar el cancer de prostata. | |
| TN2022000255A1 (en) | Pyrrolopyrimidine amines as complement inhibitors | |
| PH12023550780A1 (en) | Line-1 inhibitors to treat disease | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX2024008868A (es) | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. | |
| AR125118A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| MX2025008428A (es) | Derivados de piperidina como inhibidores de mettl3 | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2025004221A (es) | Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos | |
| MX2022016516A (es) | Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| MX2025006420A (es) | Inhibidores de adar1 y métodos de uso de estos | |
| WO2024151638A3 (en) | Compounds for fgfrs inhibitors |